Quick Facts: Danium

• Main Uses: Management of anxiety, acute alcohol withdrawal, and relief of muscle spasm.
• Other Applications: Adjunctive treatment for certain convulsive disorders.

---

What Danium Treats: Main Uses and Benefits

Danium is a prescription medication utilized in therapeutic regimens for various conditions. It is indicated for the short-term relief of symptoms of anxiety and for the comprehensive management of anxiety disorders. The medication is not typically required for anxiety or tension arising from the common stresses of daily living.

In acute alcohol withdrawal settings, Danium may be incorporated to provide symptomatic relief for associated conditions. These can include acute agitation, tremor, impending or acute delirium tremens, and hallucinosis. Additionally, Danium is a helpful adjunctive therapy to facilitate the relief of skeletal muscle spasm.

Muscle spasms addressed by this medication may be linked to reflex spasm caused by local pathology, such as inflammation or secondary to trauma. It is also used in cases of spasticity that arise from upper motor neuron disorders, including conditions like cerebral palsy and paraplegia, as well as athetosis and stiff-man syndrome. Danium may also be administered adjunctively in the management of convulsive disorders, although it is not considered an appropriate standalone treatment option for these conditions. Therapy for all indications should be undertaken under the supervision of a qualified healthcare provider.

Danium's eligibility is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status.

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Patients with a history of hypersensitivity to Danium (clobazam) or any component of the formulation.
Absolute Contraindication	Patients with severe hepatic impairment, severe respiratory insufficiency, myasthenia gravis, or sleep apnoea syndrome (stated by certain regulatory labels).

---

Age- and Condition-Based Eligibility

• Adults and Children: The medication is approved for use in patients 2 years of age and older. Safety and effectiveness have not been established in children younger than 2 years of age.
• Geriatric Patients: Use requires special caution; regulatory labels often specify that slower dose escalation is necessary in patients 65 years and older.
• Organ Function: Use is restricted in patients with mild to moderate hepatic impairment and in individuals known to be CYP2C19 poor metabolizers; these groups require conditional use with monitoring. There is no regulatory experience established for patients with severe renal impairment or End Stage Renal Disease.
• Pregnancy and Lactation: Use is generally not recommended or contraindicated during the first trimester of pregnancy and during breastfeeding, as the drug is found in human milk. Monitoring for neonatal effects is advised when used later in pregnancy.

Danium Interactions with other medicines and products

The official regulatory profile for Danium (Clobazam) details specific interactions categorized by pharmacodynamic and pharmacokinetic mechanisms. A critical high-risk pharmacodynamic interaction exists with Opioids and other Central Nervous System (CNS) Depressants. Co-administration with these substances, including alcohol, is officially associated with a risk of profound sedation, respiratory depression, and coma, a severe restriction documented in the regulatory Boxed Warning. Alcohol consumption also carries a pharmacokinetic risk, documented as increasing Clobazam blood levels by approximately 50%.

---

Danium's interaction profile is also defined by the CYP450 enzyme system. Danium is documented as a weak inhibitor of CYP2D6, an interaction that can increase the systemic plasma exposure of other medicines that are primarily metabolized by this enzyme (CYP2D6 substrates). Conversely, Danium is metabolized by CYP2C19, and its active metabolite, N-desmethylclobazam, experiences increased plasma levels when co-administered with strong or moderate CYP2C19 inhibitors, such as Cannabidiol (CBD). This clinically significant increase in exposure is also observed in patient populations identified as CYP2C19 poor metabolizers and those with mild to moderate hepatic impairment. The regulatory label further notes that Danium can be taken with or without food, as no administration restriction is imposed based on meals.

Mechanism of Action: Selective Complement Inhibition

Danium functions as a selective inhibitor that targets Complement factor D (fD), a key serine protease within the innate immune system. This targeted molecular interaction disrupts the catalytic site of fD, thereby preventing the enzyme's ability to cleave factor B.

This inhibition modulates the Alternative Pathway (AP) of the complement cascade. By blocking the fD-mediated cleavage of factor B, Danium prevents the assembly of the C3 convertase enzyme (C3bBb) . The absence of functional C3 convertase limits the amplification of the AP response and reduces the subsequent generation of C3 fragments.

The mechanistic cascade culminates in a decreased rate of opsonization, the process by which complement component C3 fragments bind to the surface of circulating blood cells. This reduced complement tagging limits macrophage-mediated extravascular hemolysis (EVH), thereby shifting the physiological rate of red blood cell clearance.

How to Use Danium

Administration Scope and Forms

Danium (Clobazam) is for the oral route of administration via several forms: a conventional tablet, an oral suspension (liquid), and an oral soluble film. The tablets may be swallowed whole, broken in half, or crushed and mixed with soft food, such as applesauce. The oral soluble film is placed on the tongue to dissolve and does not require liquid. The oral suspension must be shaken well before use and measured only with the specialized dosing syringe provided. The medication can be taken with or without food.

Standard Dosing and Scheduling

Standard dosing is based on body weight for specific indications. The recommended starting dose for adult patients over 30 kg is typically 10 mg once daily. For total daily doses exceeding 5 mg, the medication is administered in two divided doses (twice daily). For epilepsy regimens, the largest dose is often recommended for nighttime administration. Dose adjustment (titration) proceeds gradually, with increases occurring no more rapidly than weekly.

Population-Specific Use and Duration

Established protocols include specific dose reductions for certain groups. For older adults (geriatric patients) and those with hepatic impairment, the initial starting dose is 5 mg/day, and titration proceeds more slowly toward a maintenance dose that is typically half the standard dose. Furthermore, while used long-term for adjunctive seizure treatment, use for anxiety relief is a short-term course, generally not exceeding four weeks. Abrupt cessation is avoided; the dose is gradually tapered over time.

Research Evidence / Overview of Studies for Danium (Clobazam)

Evidence for Use in Convulsive Disorders (Epilepsy)

Research exploring Danium's characteristics as an add-on therapy for certain convulsive disorders, particularly Lennox-Gastaut Syndrome (LGS), has been primarily drawn from short-term randomized, double-blind, placebo-controlled trials (RCTs). These studies included both children (aged two years and older) and adults. Researchers focused on outcomes related to physical discomfort, such as measuring the weekly frequency of drop seizures and observing the proportion of subjects who achieved a change in seizure measurements. Following these initial RCTs, many subjects were observed in long-term open-label extension studies to monitor how symptoms evolved in the observed populations over extended observation.

Evidence for Relief of Anxiety and Alcohol Withdrawal Symptoms

Danium has also been studied for the short-term relief of anxiety symptoms and in research examining temporary physiological imbalance during acute alcohol withdrawal. The research exploring short-term symptom changes in anxiety has involved randomized, double-blind trials. For acute alcohol withdrawal, research focused on comparative group studies against other standard-of-care treatments. Findings described patterns observed in the studies, often indicating that outcomes measured were similar to those observed with other medications used in these acute settings.

Research Gaps and Areas of Uncertainty

The body of research provides insight into short-term changes, but specific areas of uncertainty remain. A primary limitation is that follow-up durations were limited in many controlled studies, meaning long-term effects are not fully established by controlled means. Furthermore, data for certain groups remain insufficient; for instance, limited dedicated studies address Danium's observed characteristics in older adults or populations with specific comorbid conditions. The comparative evidence is lacking in large-scale, head-to-head trials against newer treatments for epilepsy or other conditions.

Key Studies & References

1. Clobazam (Oral Route) - MedlinePlus Drug Information, used for general therapeutic purpose, anxiety, and muscle spasm

Common questions about Danium (FAQ)

---

Q: How long does it typically take for Danium to start producing effects?

The time it takes for Danium to begin working can vary for each person. Official clinical pharmacology information notes that the medicine is metabolized into an active form, N-desmethylclobazam, which contributes to its long-acting profile. This feature is understood to contribute to the sustained action of the medicine.

---

Q: Is Danium intended for short-term or long-term use?

The authorized duration of use for Danium depends on the medical condition it is addressing. Official product information indicates that for use as an add-on treatment for certain convulsive disorders, it is generally used long-term. However, for the relief of anxiety symptoms, official use is defined as a short-term course, typically not exceeding four weeks.

---

Q: Are the side effects of Danium usually temporary?

Official documents and safety summaries describe the adverse effects that were observed during clinical trials. However, regulatory documents do not generally specify the typical duration or expected resolution timeframe for most side effects.

---

Q: How often do people experience stomach upset when taking Danium?

Gastrointestinal effects are listed in the official safety profile. Specifically, regulatory documents classify Constipation as a Very Common adverse reaction, while Vomiting is classified as a Common adverse reaction.

---

Q: What are the official restrictions for Danium use during pregnancy?

Official prescribing information indicates that use of Danium is generally not recommended or may be contraindicated during the first three months of pregnancy. If the medicine is used later in pregnancy, monitoring for potential effects in the newborn is officially advised.

---

Q: Is Danium secreted into breast milk, and what are the official recommendations?

Yes, the active ingredient in Danium is found in human milk. Because of this, official information states that the use of Danium is generally not recommended or may be contraindicated while breastfeeding.

---

Q: What are the official guidelines for using Danium in patients with liver problems?

The official regulatory label mandates different usage guidelines based on the severity of the condition. Danium is absolutely contraindicated, which means it is not authorized for use, in patients with severe hepatic impairment. For patients with mild to moderate hepatic impairment, a lower initial starting dose and a slower dose increase are officially specified.

---

Q: Where can I find the results of the main clinical trials for Danium?

Regulatory documents confirm that studies were conducted to support the drug's use. Official research results are typically made public through government-run clinical trial registries or official medical literature databases, such as the NIH MedlinePlus.

---

Q: How does Danium compare to other existing medicines used for the same condition?

Official regulatory summaries of the research evidence note that the body of study has limitations in this area. Specifically, the evidence indicates that large-scale, head-to-head comparative trials are lacking against newer treatments for the conditions Danium addresses.

---

Q: Is Danium known to affect sleep patterns?

Yes, official prescribing information notes several effects related to sleep and alertness. Somnolence (Sedation) and Lethargy are classified as Very Common side effects, and Insomnia is classified as a Common side effect.

---

Q: Is Danium considered a first-line or second-line treatment?

Research documents describe Danium's characteristics as an add-on therapy (adjunctive treatment) for certain convulsive disorders. This indicates that it is generally used as an additional treatment to primary therapies.

---

Q: What happens if a dose of Danium is missed?

The official instructions generally state that the medicine should be resumed at the next regularly scheduled time. They further clarify that two doses should not be taken to compensate for the dose that was missed.

---

Q: Is it necessary to take Danium at the exact same time every day?

Official dosing recommendations state that for total daily doses exceeding 5 mg, the medication is directed to be administered in two divided doses. The regulatory label further notes that the largest dose is often recommended for nighttime administration to manage potential sedation.

---

Q: What are the signs of a severe allergic reaction to Danium?

The FDA Patient Medication Guide describes the signs of a severe reaction. These signs typically include: hives, rash, difficulty breathing, swelling of the face, lips, tongue, or throat, and fever.

---

Q: Does Danium interact with common over-the-counter pain relievers?

Danium is documented as a weak inhibitor of CYP2D6, which is a liver enzyme that metabolizes (processes) many other medicines, including some common pain relievers. This interaction may potentially increase the level of other drugs in the body. The official labeling contains a full list of known drug-drug interactions.

---

Q: Does Danium interact with dietary supplements or herbal products?

Yes, official prescribing information specifically notes a clinically significant interaction with Cannabidiol (CBD). This interaction is due to CBD's effect on the CYP2C19 enzyme system, which can increase the systemic exposure of Danium’s active metabolite.

---

Q: Is Danium the same as the generic version of the medicine?

Danium is the brand name used for the medicine, and its active ingredient is Clobazam. Clobazam is the established generic name for the same chemical substance.

---

Q: Is Danium considered a controlled substance?

Yes, official safety information and storage guidelines explicitly state that Danium is regulated as a controlled substance. This means its distribution and use are monitored by government health authorities due to the potential risks of abuse, misuse, and dependence.

---

Q: What should be done if Danium does not seem to be relieving symptoms?

Official documents advise that if there is a concern that the medicine is not providing the expected relief, they suggest consulting a healthcare provider. This allows for a discussion of the ongoing symptoms and the possible need for a change or adjustment to the treatment.

How to Store and Dispose of Danium (Clobazam)

Storage Conditions

Danium must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept from freezing and protected from heat, moisture, and direct light. For safety, Danium is a controlled substance and must be stored in a safe place and kept out of the reach of children.

Oral Suspension and Stability

The oral suspension must be stored upright in its original bottle and shaken well before each use. It is mandatory to discard any unused oral suspension 90 days after the bottle is first opened.

Disposal

All unused or expired Danium must be safely disposed of in accordance with local requirements. The medicine should generally not be thrown away via wastewater or household waste unless specifically instructed by regulatory authorities.